Patient and data collection experts Kayentis net €3.6 million in latest funding round led by Innovation Capital
Kayentis, the global provider of solutions ECOA (electronic Clinical Outcome Assessment) for the patient and data collection in clinical trials have announced the completion of a financing round of € 3.6 million.
The tour is conducted by Innovation Capital contributes the vast majority of the funding through its SISA funds dedicated to the digital health companies in Europe. Existing investors, Extens, Lénapart and KCE also participated in the round.
Kayentis ECOA is a specialist in solutions for the patient and data collection in clinical trials since 2009. The company has developed a full range of services and expanded its portfolio of solutions to serve the pharmaceutical industry, biotechnology companies and CROs.
With the experience of over 120 clinical trials in 75 countries (6 000 sites and 50,000 patients) and in a number of therapeutic areas, Kayentis adds value to data quality and efficiency of clinical trial through innovative and intuitive solutions and with two priorities in its development: Patient Engagement and Risk-based Monitoring.
The funds raised will enable Kayentis accelerate its international growth by increasing its investments in sales, marketing and R & D, and to position the company as a leading supplier of solutions in the world ECOA.
“This financing round validates our business model and growth prospects. It also gives Kayentis ways to continue to improve its technology platform and value-added services to better serve its customers worldwide. I am particularly pleased to welcome Innovation Capital as an investor and partner to accompany us in this new phase of growth for Kayentis. I also want to thank existing investors of the company for their continued support, ” said William Judge, President of Kayentis.
Franck Noiret, Associate Director of Innovation Capital, said: “We are delighted to partner with Kayentis and experienced leaders. This is the 7 th investment of our funds SISA dedicated to financing innovative companies in digital health in Europe. Kayentis achieved impressive record in recent years and we are confident that the company will continue to grow strongly. Kayentis has what it takes to become in the next years one of the largest providers of ECOA solutions worldwide. ”
“Thanks to its portfolio of solutions and reliability of its service, Kayentis has perfectly managed to become the partner of choice in the clinical trial industry. The strong development of the company reinforces our decision two years ago to accompany him. We reinvest enthusiastically in order to Kayentis a major player in the ECOA internationally. ” Adds Arnaud Houette, Partner Manager of Extens.
Kayentis ECOA is a specialist in solutions for the patient and data collection in clinical trials since 2009. Founded in 2003, the company has developed a full range of services and expanded its portfolio of solutions to serve the pharmaceutical industry, companies biotech and CROs. Today, with the experience of over 120 clinical trials in 75 countries (6 000 sites and 50,000 patients) and in a number of therapeutic areas, Kayentis adds value to the quality of data and the efficiency of the clinical trial through innovative and intuitive solutions, and with two priorities in its development: Patient Engagement and Risk-based Monitoring.
Source: Innovation Capital Press Release